| 1 | Agrippal S1 (Influenza vaccination) | - | - | - | - | [1] 46 46 |
| 2 | Belimumab plus Early Vaccination | [1] Belimumab Belimumab | [1] D03068
D03068
| [1] TNFSF13B TNFSF13B 💬 | [4] Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis 💬 | [1] 49 49 |
| 3 | Belimumab plus Late Vaccination | [1] Belimumab Belimumab | [1] D03068
D03068
| [1] TNFSF13B TNFSF13B 💬 | [4] Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis 💬 | [1] 49 49 |
| 4 | COVID-19 vaccination | - | - | - | - | [1] 13 13 |
| 5 | Human papillomavirus vaccination (Gardasil) | [1] Human papillomavirus type 6 L1 capsid protein antigen Human papillomavirus type 6 L1 capsid protein antigen | - | - | - | [1] 49 49 |
| 6 | Influenza vaccination | - | - | - | - | [1] 299 299 |
| 7 | Measles, Mumps, Rubella vaccination | - | - | - | - | [1] 107 107 |
| 8 | Multiple (4 autologous subcutaneous T cell vaccinations with T cell lines reactive to nine myelin peptides) | - | - | - | - | [1] 13 13 |
| 9 | Prevenar vaccination | - | - | - | - | [1] 46 46 |
| 10 | T cell vaccination | - | - | - | - | [1] 13 13 |
| 11 | T-Cell Vaccination | - | - | - | - | [1] 13 13 |
| 12 | Vaccination | - | - | - | - | [1] 49 49 |
| 13 | Vaccination against TBE | - | - | - | - | [1] 46 46 |
| 14 | Vaccination with vaccine against hepatitis A and B | - | - | - | - | [1] 299 299 |